Immunetrics can predict the probability of achieving efficacy endpoints, for any point in time, over any range of population sizes. This service is invaluable in trial design, as it indicates the minimum number of patients necessary to achieve a given probability of success. We can identify the success criteria and number of enrolled patients that satisfy any definition of acceptable risk.

Unlike traditional statistical power analysis, Immunetrics does not assume that prior observed results are true:

  • Individual patients are simulated in detail over all relevant trial scenarios
  • The biology of the model dictates future predictions, not the prior observations
  • This lends to the model being able to highlight any Type I (false positive) errors in earlier trials